SWM
KPTI icon

SeaCrest Wealth Management’s Karyopharm Therapeutics KPTI Stock Holding History

SeaCrest Wealth Management’s Portfolio KPTI Stock Details KPTI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-52
Closed -$5K – 1228
2019
Q1 		$5K Hold
52
– – ﹤0.01% 1722
2018
Q4 		$7K Hold
52
– – ﹤0.01% 1596
2018
Q3 		$13K Hold
52
– – ﹤0.01% 1542
2018
Q2 		$13K Hold
52
– – ﹤0.01% 1511
2018
Q1 		$11K Hold
52
– – ﹤0.01% 1548
2017
Q4 		$8K Buy
+52
New +$8.35K ﹤0.01% 1674

Other funds holding KPTI

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $78.1B AUM 55.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
EA
Emerald Advisers Leola, Pennsylvania $3.16B AUM 109.58% 1-Year Est. Return
EMFAT
Emerald Mutual Fund Advisers Trust Leola, Pennsylvania $2.06B AUM 106.87% 1-Year Est. Return

SeaCrest Wealth Management's KPTI Position: Q2 2019 in Review

SeaCrest Wealth Management sold out of Karyopharm Therapeutics (KPTI) in Q2 2019, closing a stake of 52 shares — an estimated $5K sold.

SeaCrest Wealth Management first reported a position in KPTI in Q4 2017 and held it in 6 quarters. The position peaked at $13K in Q3 2018. 103 funds tracked by Wall St. Rank hold KPTI as of Q2 2019.

  • SeaCrest Wealth Management reported no remaining Karyopharm Therapeutics position as of Q2 2019 after selling out during the quarter.
  • SeaCrest Wealth Management sold 52 Karyopharm Therapeutics shares in Q2 2019, an estimated $5K.
  • SeaCrest Wealth Management first reported a position in Karyopharm Therapeutics in Q4 2017 and held it in 6 quarters.
  • SeaCrest Wealth Management's Karyopharm Therapeutics position peaked at $13K in Q3 2018.
  • 103 funds tracked by Wall St. Rank held Karyopharm Therapeutics as of Q2 2019.

Based on SeaCrest Wealth Management's 13F filing for Q2 2019, filed 19 Jul 2019.